MENU

BDTX Stock Black Diamond Therapeutics (BDTX, $5.44) entered Downtrend as Momentum indicator drops below 0 level on May 15, 2024

A.I.dvisor
at Tickeron.com
05/16/24
Loading...
BDTX - Black Diamond Therapeutics
Momentum signal
Bearish Trend
Odds of DOWN Trend
Tickeron
Momentum signal
Price: $5.44
Daily change: -$0.3 (-5.23%)
Daily volume: 2.5M
Capitalization: $306.1M
Industry: Biotechnology
This indicator may be signaling that BDTX's price has further to drop, since it fell below its price logged 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options. A.I.dvisor backtested 67 similar cases where BDTX's Momentum Indicator fell below the 0 level, and of them led to a successful outcome. Odds of Success:

BDTX saw its Stochastic Oscillator recovers from the overbought zone

The Stochastic Oscillator for BDTX moved out of overbought territory on November 14, 2024. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 50 similar instances where the indicator exited the overbought zone. In of the 50 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 50-day moving average for BDTX moved below the 200-day moving average on October 22, 2024. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BDTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for BDTX entered a downward trend on November 11, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BDTX's RSI Indicator exited the oversold zone, of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on November 06, 2024. You may want to consider a long position or call options on BDTX as a result. In of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for BDTX just turned positive on October 18, 2024. Looking at past instances where BDTX's MACD turned positive, the stock continued to rise in of 39 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BDTX advanced for three days, in of 243 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.655) is normal, around the industry mean (14.655). P/E Ratio (0.000) is within average values for comparable stocks, (96.848). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.824). BDTX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (0.000) is also within normal values, averaging (218.428).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. BDTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BDTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

View a ticker or compare two or three
BDTX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a biotechnology company that discovers and develops therapeutic agents to target unique oncogenic protein-isoforms.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
One Main Street
Phone
+1 617 252-0848
Employees
54
Web
https://www.blackdiamondtherapeutics.com